Abstract
Novo Nordisk publishes research plans from which some directions for the development of diabetes treatment can be derived. There is a constant effort to achieve the etiopathogenetic treatment of type 1 diabetes, in the treatment of type 2 diabetes there is an emphasis on the use of new types of insulin (once a week - insulin icodec, insulin affecting the reactivity of blood vessels).
A new amylin analog in combination with semaglutide is a promising antiobesity drug. The benefit of a gastrointestinal polypeptide analog in combination with semaglutide is being investigated.
For practice, the fixed combination of one-week insulin icodec with semaglutide will probably be of greatest benefit.